MedTrace Logo

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

NCT07525947 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-13

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.

Conditions

  • Healthy Volunteers (HV)

Interventions

DRUG

JADE101

JADE101 is supplied as sterile solution to be administered by SC injection

Sponsors & Collaborators

  • Jade Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Li Li, MD · Jade Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07525947 on ClinicalTrials.gov